<DOC>
	<DOCNO>NCT01793870</DOCNO>
	<brief_summary>This randomize , open-label , single dose , 4-period , period balance , crossover study . There least 5 day dose session . The study consist Screening period ( 30 day prior Day 1 ) , Treatment period consist 4 dose period ( Day 1 dose day Day 2 ) Follow-up period ( 7-14 day post-last dose ) . The detailed treatment regimen A B ( 27.5 mg total maximum dose ) : Single oral dose carvedilol 25 mg immediate release tablet 2.5 mg enrich carvedilol powder fast condition ; C ( 33.75 mg total maximum dose ) : Single oral dose carvedilol 31.25 mg 25 mg immediate release tablet , 6.25 mg immediate release tablet 2.5 mg enrich carvedilol powder fast condition ; D ( 27.5 mg total maximum dose ) : Single oral dose carvedilol 25 mg immediate release tablet 2.5 mg enrich carvedilol powder feed condition . Approximately 15 subject randomize receive one four treatment sequence ( ADBC , BACD , CBDA , DCAB ) . The pharmacokinetic sampling safety data collect Treatment period ( Day 1 2 ) .</brief_summary>
	<brief_title>A Study Healthy Volunteers Evaluate Application Stable Isotope Approach Reduce Number Subjects Needed PK Studies</brief_title>
	<detailed_description />
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Inclusion criterion Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test ECG monitoring . Male female 18 55 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential Female subject child bear potential must agree use contraception screen followup visit . Male subject female partner childbearing potential must agree use one contraception method . Body weight &gt; = 50 kilogram ( kg ) BMI within range 18.5 29.9 kilogram per meter square ( kg/m^2 ) ( inclusive ) . Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Average QT correct use Bazett 's formula ( QTcB ) QT correct use Fridericia 's formula ( QTcF ) &lt; 450 millisecond ( msec ) . Suitable cannulation adequate venous access . Exclusion criteria A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Resting heart rate &lt; 50 beat per minute ( bpm ) screen Any follow abnormality 12lead electrocardiogram ( ECG ) screening : conduction abnormality denote follow PR interval &lt; 120 msec &gt; 200 msec ; nonspecific IVCD ( intraventricular conduction delay ) QRS duration &gt; =110 msec morphology NOT meet criterion leave ( LBBB ) right bundle branch block ( RBBB ) ; incomplete RBBB define QRS duration &gt; =100 msec &lt; 120 msec RBBB pattern ; complete RBBB LBBB ; evidence second third degree atrio ventricular ( AV ) block ; pathological Qwaves ( Qwave wider 0.04 sec depth great 0.40.5 millivolt [ mV ] ) ; evidence ventricular preexcitation ; evidence leave axis deviation ( left axis deviation 30 90 degree ) normal leftward axis , STT wave abnormality . Documented history low blood pressure ( average systolic blood pressure [ SBP ] &lt; = 110 millimeter mercury [ mm Hg ] and/or DBP &lt; =60 mm Hg ) semisupine blood pressure value time screen . Orthostatic hypotension diagnose screening ( orthostatic hypotension define reduction systolic blood pressure 20 mm Hg and/or reduction diastolic blood pressure 10 mmHg within three minute stand upright supine screening ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 milliliter [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable adhere restriction detail informed consent protocol . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine human chorionic gonadotropin ( hCG ) test screen prior dosing . Subject smoker , base least 12 month nonsmoking history . Lactating female . Subjects asthma history asthma bronchospasm . Subjects history childhood asthma asymptomatic may include investigator discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>carvedilol</keyword>
	<keyword>Stable isotope technique</keyword>
</DOC>